ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1511

Drug Survival of Ustekinumab in Psoriatic Arthritis: A Real-World Multicentric Cohort of 252 Patients

Jean-Guillaume Letarouilly1, Benoit Flachaire 2, Céline Labadie 3, Jérémie Sellam 4, Pascal Richette 5, Philippe Dieudé 6, Pascal Claudepierre 7, Bruno Fautrel 8, Eric Houvenagel 9, Chi Duc Nguyen 10, Marie-Hélène Guyot 11, Nicolas Segaud 12, Frédéric Maury 13, Laurent Marguerie 14, Xavier Deprez 15, Jean-Hugues Salmon 16, Guy Baudens 17, Elisabeth Gervais 18, Isabelle Chary-Valckenaere 19, Pierre Lafforgue 20, Damien Loeuille 21, Christophe Richez 22, Thao Pham 20 and René-Marc Flipo 23, 1University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, Nord-Pas-de-Calais, France, 2Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, Provence-Alpes-Cote d'Azur, France, 3Bordeaux University, CHU Bordeaux, department of Rheumatology, 33,000 Bordeaux, France, Bordeaux, Aquitaine, France, 4Service de Rhumatologie, AP-HP Hôpital Saint-Antoine, Sorbonne Université, INSERM, Centre de Recherche Saint-Antoine, Paris, France, Paris, France, 5Department of Rheumatology, AP-HP Lariboisiere Hospital, Paris, France, 6Rheumatology, Bichat Hospital, APHP, Paris;, Paris, France, 7Rheumatology, CHU Henri Mondor Créteil, Paris, France, 8Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, 9Rheumatology, Saint Philibert Hospital, Lille Cathololic Institute, Lomme, Lomme, France, 10Rheumatology, Hospital of Béthune, Béthune, Béthune, France, 11Rheumatology, Hospital of Roubaix, Roubaix, Roubaix, France, 12Internal Medicine, Hospital of Armentières, Armentières, Armentières, France, 13Rheumatology, Private Practice, Beuvry, Beuvry, France, 14Rheumatology, Calot Institute, Berck, Berck-sur-Mer, 15Rheumatology, Hospital of Valenciennes, Valenciennes, Valenciennes, France, 16Rheumatology, Reims University Hospital, Reims, Reims, France, 17Rheumatology, Private Practice, Valenciennes, Valenciennes, France, 18CHU de Poitiers, Rheumatology, Poitiers, France, 19Centre Hospitalier Universitaire de Nancy, VANDOEUVRE, France, 20Aix-Marseille University, CHU Marseille, department of Rheumatology, 13,000 Marseille, France, Marseille, France, 21Rheumatology, Nancy University Hospital and and UMR 7365 CNRS-UL IMoPA, Université de Lorraine, VANDOEUVRE, France, 22Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France, 23University of Lille, CHU Lille, department of rheumatology, 59,000 Lille, France, Lille, France

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Biologic drugs, psoriatic arthritis and multicenter study, survival

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Treatment of Axial Spondyloarthritis & Psoriatic Arthritis

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Ustekinumab (UST) is a new biological Disease-modifying AntiRheumatic Drug (bDMARD) available in psoriatic arthritis (PsA), targeting respectively IL12-23. Real-world data are missing for this drug on the contrary to TNF inhibitors. Median drug survival of TNF inhibitors is between 10 and 12 months according to the most recent studies (1).There are only few studies with a low number of patients in UST. Studying drug survival in PsA is important, since new therapies have been launched such IL-17 inhibitors or apremilast.

Methods: This is a retrospective, national, multicentric, non-sponsored by any pharmaceutical company study from patients suffering from PsA (CASPAR criteria or diagnosis confirmed by the rheumatologist) from July 2011 to March 2019. UST has been launched in October 2014. Drug survival was defined as the time from initiation to discontinuation (stop/switch) of bDMARDs. Kaplan-Meier survival curves and Cox-regression analyses [hazard ratios (HR) and 95% confidence intervals (CIs)] were used adjusting for patient demographics, disease characteristics, corticosteroid therapy, co-therapy with methotrexate, previous line of bDMARDs posology of UST and switch to 90 mg every 3 months when patients were at 45 mg every 3 months. Reasons of discontinuation were collected and pooled as primary failure, secondary failure and adverse events. Primary inefficacy was defined as an insufficient response to treatment during the six months after the initiation. Secondary inefficacy was defined as a loss of response to treatment after an initial six-month response.

Results: 252 patients were included with a mean follow-up ≥ 6 months: 183 patients satisfy CASPAR. At baseline, the mean age was 49.2 (11.2) years old. 58% of patients were women. 49% of patients were non-smoker. The body mass index was 28.8 (6.3) kg/m². The disease duration was 10.2 (8.9) years. 44% of patients presented axial and peripheral form. 97% of patients presented psoriasis. The mean Charlson Index was 1.3 (1.5). Patients were bDMARDs-naïve in 22%, had a previous bDMARDs in 16% and more than two bDMARDs in 54% and had co-therapy with methotrexate in 39% and 27% of patients received corticosteroid therapy . Patients had a switch to 90 mg every 3 months in 10%. The mean DAS28-CRP was 3.88 (1.3) and the mean CRP was 27.5 (42.7) mg/L. The median drug survival for UST was 12 months (95%CI: 10-15) (Fig1). Baseline high CRP levels and satisfying CASPAR criteria were associated with a favorable drug survival for UST, respectively (HR=1.007, 95%CI 1.002–1.012 and HR=5.56, 95%CI 2.79-11.13), whereas disease duration and nail psoriasis were associated with an unfavorable one, respectively (HR=0.965, 95%CI 0.00–0.99 and HR=0.52, 95%CI 0.00-0.84). 14 patients under UST stopped their treatment due to side effects.

Conclusion: This real-world study for drug survival on PsA is among the studies with the largest number of patients for UST. Drug survival of UST seems similar to the survival of TNF inhibitors (1).

      (1) Walsh JA et al. Care Spec Pharm. 2018;24:623-631 

Drug survival of ustekinumab in psoriatic arthritis


Disclosure: J. Letarouilly, None; B. Flachaire, UCB pharma, BMS, Novartis, 9; C. Labadie, None; J. Sellam, Janssen, 8; P. Richette, Janssen, 8; P. Dieudé, None; P. Claudepierre, Janssen, 8; B. Fautrel, AbbVie, 2, 5, 8, Biogen, 5, 8, BMS, 5, 8, Boehringer Ingelheim, 8, Celgene, 5, 8, Eli Lilly and Company, 2, 5, Janssen, 5, 8, Lilly, 8, Medac, 5, 8, MSD, 2, 5, 8, NORDIC Pharma, 5, 8, Novartis, 5, 8, Pfizer, 2, 5, 8, Roche, 5, 8, Sanofi-Aventis, 5, SOBI, 5, 8, UCB, 5, 8; E. Houvenagel, Janssen, 8, Novartis, 8; C. Nguyen, None; M. Guyot, None; N. Segaud, None; F. Maury, None; L. Marguerie, None; X. Deprez, Janssen, 8; J. Salmon, Janssen, 8; G. Baudens, None; E. Gervais, None; I. Chary-Valckenaere, None; P. Lafforgue, Chugai, 8, Amgen, 8, BMS, 8, Lilly, 8, Abbvie, 8, Pfizer, 8, Biogaran, 8; D. Loeuille, None; C. Richez, astrazeneca, 5, 8, BMS, 5, 8, Glenmark, 5, 8, Janssen, 5, 8, Lilly, 5, 8, Pfizer, 5, 8, Roche, 5, 8, UCB, 5, 8; T. Pham, Abbvie, 8, Amgen, 8, Biogen, 8, BMS, 8, Celgene, 8, Fresenius-Kabi, 8, Janssen, 8, Lilly, 8, Medac, 8, MSD, 8, Nordic, 8, Novartis, 8, Pfizer, 8, Roche-Chugai, 8, Sandoz, 8, Sanofi, 8, UCB, 8; R. Flipo, Janssen, 8, Novartis, 8.

To cite this abstract in AMA style:

Letarouilly J, Flachaire B, Labadie C, Sellam J, Richette P, Dieudé P, Claudepierre P, Fautrel B, Houvenagel E, Nguyen C, Guyot M, Segaud N, Maury F, Marguerie L, Deprez X, Salmon J, Baudens G, Gervais E, Chary-Valckenaere I, Lafforgue P, Loeuille D, Richez C, Pham T, Flipo R. Drug Survival of Ustekinumab in Psoriatic Arthritis: A Real-World Multicentric Cohort of 252 Patients [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/drug-survival-of-ustekinumab-in-psoriatic-arthritis-a-real-world-multicentric-cohort-of-252-patients/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/drug-survival-of-ustekinumab-in-psoriatic-arthritis-a-real-world-multicentric-cohort-of-252-patients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology